Furthermore, we found significant enrichment of KRAS signaling upregulation after the TZB monotherapy and the PZB + TZB combination, which is in line with previous findings7, showing that compensatory RAS signaling activation can effectively compensate for HER3 blockage in ERBB2-dependent cancers after the TZB treatment. The gene discussed is KRAS; the disease is cancer.